Wave Life Sciences Ltd.
NASDAQ Global MarketTotal Valuation
Wave Life Sciences Ltd. carries a market capitalization of 1.11B, placing it among publicly traded companies globally. Its enterprise value stands at 761.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.11B |
| Enterprise Value | 761.71M |
Share Statistics
Wave Life Sciences Ltd. currently has 192.34M shares outstanding.
| Shares Outstanding | 192.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 17.98, and the price-to-book ratio stands at 4.70.
| PE Ratio | N/A |
| PS Ratio | 17.98 |
| PB Ratio | 4.70 |
| P/TBV Ratio | 2.52 |
| P/FCF Ratio | -7.05 |
| P/OCF Ratio | -7.01 |
Enterprise Valuation
| EV / Sales | 10.61 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Wave Life Sciences Ltd. maintains a current ratio of 11.26, meaning it holds 11.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.26 |
| Quick Ratio | 10.93 |
| Debt / Equity | 3.07 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -128.76 |
| Return on Assets (ROA) | -42.11 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Wave Life Sciences Ltd.'s stock has declined approximately -13.77246% over the past 52 weeks. The 50-day moving average sits at 7.23, while the 200-day moving average is 10.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -13.77246% |
| 50-Day Moving Average | 7.23 |
| 200-Day Moving Average | 10.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Wave Life Sciences Ltd. generated 71.80M in revenue and converted that into -183.59M in net income, yielding earnings per share of -1.03. EBITDA reached -187.88M, while operating income came in at -196.88M.
| Revenue | 71.80M |
| Gross Profit | N/A |
| Operating Income | -196.88M |
| Pretax Income | -183.59M |
| Net Income | -183.59M |
| EBITDA | -187.88M |
| EBIT | -196.88M |
| Earnings Per Share (EPS) | -1.03 |
Balance Sheet
Wave Life Sciences Ltd. holds 544.59M in cash and equivalents against 15.72M in total debt, resulting in a net debt position of -544.59M. Total book value stands at 274.56M, with working capital of 511.44M providing operational flexibility.
| Cash & Cash Equivalents | 544.59M |
| Total Debt | 15.72M |
| Net Debt | -544.59M |
| Equity (Book Value) | 274.56M |
| Book Value Per Share | 1.54 |
| Working Capital | 511.44M |
Cash Flow
Wave Life Sciences Ltd. produced -184.01M in operating cash flow over the past twelve months. After subtracting -991,000.00 in capital expenditures, free cash flow totaled -185.00M - equivalent to -1.04 per share.
| Operating Cash Flow | -184.01M |
| Capital Expenditures | -991,000.00 |
| Free Cash Flow | -185.00M |
| FCF Per Share | -1.04 |
Margins
Wave Life Sciences Ltd. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -274.21 and net profit margin of -255.70 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -274.21 |
| Pretax Margin | -255.70 |
| Profit Margin | -255.70 |
| EBITDA Margin | -261.68 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -37.70 |
| FCF Yield | -14.18 |
Scores
Wave Life Sciences Ltd. posts an Altman Z-Score of 7.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.60 |